



Companion Diagnostic Testing

Tumors that require PD-L1 testing for “on-label” use of pembrolizumab, cemiplimab, or nivolumab plus ipilimumab



Complementary Diagnostic Testing

PD-L1 testing is NOT required for the use of nivolumab in patients with these tumors, but testing is available



Abbreviations

CPS	Combined positive score
ESCC	Esophageal squamous cell carcinoma
FDA	U.S. Food and Drug Administration
HNSCC	Head and neck squamous cell carcinoma
IHC	Immunohistochemistry
MMR	Mismatch repair
MSI	Microsatellite instability
NSCLC	Non-small cell lung cancer
PD-L1	Programmed death-ligand 1
TNBC	Triple-negative breast cancer
TPS	Tumor proportion score

^aMSI/MMR-deficient tumors: KEYTRUDA has been approved for these tumors, irrespective of site. No PD-L1 testing is required. Testing to establish MSI/MMR-deficient status is required.

^bMSI/MMR-deficient colorectal carcinomas: OPDIVO alone or in combination with YERVOY has been approved for these cancers. No PD-L1 testing is required. Testing to establish MSI/MMR-deficient status is required.